Company Active LTD

Company profile

Nanovery Limited

Nanovery

Nanovery Limited is a UK company with status active founded in 2018 based in North East England.

CRN
11695725
Founded
2018
Age
7

Overview

Legal name
NANOVERY LIMITED
Region
North East England
Registered address
THE BIOSPHERE
DRAYMANS WAY, NEWCASTLE HELIX
NEWCASTLE UPON TYNE
TYNE AND WEAR
ENGLAND
NE4 5BX
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

4 levels 2 ultimate controllers
1
Company Active LTD
Nanovery Limited
CRN 11695725
2
Direct controller Active LTD
Innovation GP Limited
CRN 10428104
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
5
Ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION
6
Ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

5 events
02 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2026

Accounts due

Accounts Due

Next accounts due date

19 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Nov
2024

Accounts filed

Accounts

Last accounts made up date

26 Nov
2018

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2021
Funded years
2021, 2022, 2025
Age at first award
2 years

Projects

2025 Collaborative R&D Lead participant

ML to accellerate nanorobotics in drug development

1 May 2025 to 31 Oct 2026

Awarded
£528,083
Total cost £754,404

A rising class of drugs 'Oligonucleotide Therapeutics'(OTs) offer the potential of treatments tailored to specific genetic sequences of patients, alleviating unique genetic disorders and hard-to-treat diseases. The biggest challenge OTs face is delivery to target tissues in sufficient quantities. To overcome this, developers have implemented complex chemi...

2022 Investment Accelerator Lead participant

DNA Nanorobots for Screening and Monitoring of Noncommunicable Diseases

1 Oct 2022 to 31 Mar 2024

Awarded
£748,954
Total cost £1,497,909

Chronic diseases are responsible for significant incapacities, suffering, and deaths worldwide and impose a severe economic burden on the nation's health systems. They may be prevented, treated, or even cured if detected on time. While medical imaging and surgical tissue biopsies remain the gold standard in disease diagnostics, these approaches are imprac...

2022 Investment Accelerator Lead participant

DNA Nanorobots for Screening and Monitoring of Noncommunicable Diseases

1 Oct 2022 to 30 Sep 2024

Awarded
£748,950
Total cost £1,497,901

Chronic diseases are responsible for significant incapacities, suffering, and deaths worldwide and impose a severe economic burden on the nation's health systems. They may be prevented, treated, or even cured if detected on time. While medical imaging and surgical tissue biopsies remain the gold standard in disease diagnostics, these approaches are imprac...

2021 Collaborative R&D Lead participant

Nanorobotic biosensors platform for disease biomarker detection (Resilience Fund)

1 Dec 2021 to 31 Jan 2022

Awarded
£98,981
Total cost £98,981

Nanovery is making use of emerging developments in nanorobotics to develop new approaches to diagnosing the world's deadliest diseases, starting with cancer. Early detection together with close tracking of cancer progression and response to treatment greatly improves a patient's experience and chances of recovery. Medical imaging and surgical tissue biops...

2021 Collaborative R&D Lead participant

Nanorobotic biosensors platform for disease biomarker detection

1 Apr 2021 to 31 Mar 2022

Awarded
£150,000
Total cost £300,000

Product types

Collaborative R&D Investment Accelerator